Tyrosine 1045 Codon Mutations in Exon 27 of EGFR are Infrequent in Oral Squamous Cell Carcinomas

  • Tushar, Mehta Dhaval (Human Genetics Laboratory, Sree Balaji Medical and Dental College and Hospital, Bharath University) ;
  • Ramanathan, Arvind (Human Genetics Laboratory, Sree Balaji Medical and Dental College and Hospital, Bharath University)
  • Published : 2013.07.30


Background: The activation and inactivation of receptor tyrosine kinases are tightly regulated to ensure faithful replication of cells. After having transduced extracellular growth activating signals, activated EGFR is subjected to downregulation either by clathrin mediated endocytosis or c-Cbl mediated proteasome degradation depending on the ligand concentration. c-Cbl is an ubiquitin ligase which requires a phosphorylated tyrosine residue at position 1045 in the cytoplasmic domain of EGFR to interact and add ubiquitin molecules. While activating mutations in exons 19 and 21 have been associated with the development of several cancers, the status of mutations at tyrosine 1045 coding exon 27 of EGFR remain to be investigated. Consistently, defective phosphorylation at 1045 has been associated with sustained phosphorylation of EGFR in non-small lung carcinomas. Hence in the present study we investigated the genetic status of the tyrosine 1045 coding site within exon 27 of EGFR gene to explore for possible occurrence of mutations in this region, especially since no studies have addressed this issue so far. Materials and Methods: Tumor chromosomal DNA isolated from thirty five surgically excised oral squamous cell carcinoma tissues was subjected to PCR amplification with intronic primers flanking the tyrosine 1045 coding exon 27 of EGFR gene. The PCR amplicons were subsequently subjected to direct sequencing to elucidate the mutation status. Results: Sequence analysis identified no mutations in the tyrosine 1045 codon of EGFR in any of the thirty five samples that were analyzed. Conclusions: The lack of identification of mutation in the tyrosine 1045 codon of EGFR suggests that mutations in this region may be relatively rare in oral squamous cell carcinomas. To the best of our knowledge, this study is the first to have explored the genetic status of exon 27 of EGFR in oral squamous cell carcinoma tissue samples.


EGFR expression in oral carcinoma;tyrosine 1045 mutation;tyrosine 1045 phosphorylation


  1. Abella JV, Park M (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab, 296, 973-84.
  2. Burgess AW (2008). EGFR family: structure physiology signaling and therapeutic targets. Growth Factors, 26, 263-74.
  3. Castillo L, Etienne-Grimaldi MC, Fischel JL, et al (2004). Pharmacological background of EGFR targeting. Ann Oncol, 15, 1007-12.
  4. de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001). c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytotic route. J Cell Science, 114, 2167-78.
  5. de Melker AA, van der Horst G, Borst J (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem, 279, 55465-73.
  6. El-Rayes BF, LoRusso PM (2004). Targeting the epidermal growth factor receptor. Bri J Cancer, 91, 418-24.
  7. Fukazawa T, Miyake S, Bandi V, Band H (1996). Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) Stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem, 271, 14554-9.
  8. Glogowska A, Stetefeld J, Weber E, et al (2012). Epidermal growth factor cytoplasmic domain affects erbb protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia, 14, 336-409.
  9. Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther, 5, 1361-8.
  10. Hosaka T, Inoue F, Ando K, et al (2007). Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer Res, 27, 2253-64.
  11. Huang F, Sorkin A (2005). Growth factor receptor binding protein 2 mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell, 16, 1268-81.
  12. Huang F, Goh LK, Sorkin A (2007). EGF receptor ubiquitination is not necessary for its internalization. PNAS, 104, 16904-9.
  13. Jayaraman B, Valiathan GM, Jayakumar K, et al (2012). Lack of mutation in p53 and H-ras genes in phenytoin induced gingival overgrowth suggests its non cancerous nature. Asian Pac J Cancer Prev, 13, 5535-8.
  14. Kim YT, Park SW, Kim JW (2002). Correlation between expression of EGFR and the prognosis of patients with cervical cancer. Gynecol Oncol, 87, 84-9.
  15. Kirisits A, Pils D, Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. nt J Biochem Cell Biol, 39, 2173-82.
  16. Kirkegaard T, Jaattela M (2009). Lysosomal involvement in cell death and cancer. Biochim Biophys Acta, 1793, 746-54.
  17. Leahy DJ (2004). Structure and Function of the Epidermal Growth Factor (egf/erbb) family of receptors. Adv Protein Chem, 68, 1-27.
  18. Lipkowitz S (2002). The role of the ubiquitination-proteasome pathway in breast cancer Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res, 5, 8-15.
  19. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S et al (2010). Heterozygous germline mutations in the CBL tumorsuppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet, 87, 250-7.
  20. McMillen E, Ye F, Li G, Wu Y, Kin G et al (2010). Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res, 36, 531-7.
  21. Murugan AK, Munirajan AK, Tsuchida N (2012). Ras oncogenes in oral cancer: the past 20 years. Oral Oncol, 48, 383-92.
  22. Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 336, 2-16.
  23. Ogiso H, Ishitani R, Nureki O, et al (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-87.
  24. Pennock S, Wang Z (2008). A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Molecular and Cell Biology, 28, 3020-37.
  25. Rajendran S, Muthupalani RS, Ramanathan A (2013). Lack of RING finger domain (RFD) Mutations of the c-Cbl gene in oral squamous cell carcinomas in Chennai, India. Asian Pac J Cancer Prev, 14, 1073-5.
  26. Rubin C, Gur G, Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res, 15, 66-71.
  27. Sigismund S, Confalonieri S, Ciliberto A, et al (2012). Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 92, 273-366.
  28. Soonthornthum T, Arias-Pulido H, Joste N, et al (2011). Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol, 10, 2166-78.
  29. Valiathan GM, Thenumgal SJ, Jayaraman B, et al (2012). Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 13, 6155-7.
  30. Visser Smit GD, Place TL, Cole SL, et al (2009). Cbl controls EGFR fate by regulating early endosome. Sci Signal, 2, 86.
  31. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8, 1197-206.
  32. Woelk T, Sigismund S, Penengo L, Polo S (2007). The ubiquitination code: a signalling problem. Cell Division, 2, 11.

Cited by

  1. BRD7 Promoter Hypermethylation as an Indicator of Well Differentiated Oral Squamous Cell Carcinomas vol.16, pp.4, 2015,